Latest News & Features
Americas
The US Supreme Court has heard oral arguments on whether genetic material is patent eligible subject matter. Jennifer Camacho, shareholder at Greenberg Traurig, reports on Monday's proceedings. 16 April 2013
Americas
Myriad Genetics will deliver an oral argument at the US Supreme Court today defending its patents covering isolated human gene sequences linked to breast and ovarian cancer. 15 April 2013
Americas
The US Patent and Trademark Office has announced the winners of its Patents for Humanity competition, which recognises patent owners and licensees addressing global health and development challenges. 12 April 2013
Asia
Merck is the latest multinational pharma company to suffer a setback in India, after failing to win an injunction against generic versions of two anti-diabetes drugs. 8 April 2013
Americas
The US Court of Appeals for the Federal Circuit has reversed a $482 million jury decision against Johnson & Johnson subsidiary Cordis, ruling that its Cypher stent did not infringe a patent held by radiologist Bruce Saffran. 8 April 2013
Asia
India’s Supreme Court has rejected pharmaceutical company Novartis’s application to patent an updated version of its leukaemia drug Glivec, agreeing with the Comptroller General that it lacked novelty. 3 April 2013
Asia
India’s patent office has published final guidelines for examining biotechnology patents, after accepting comments on a draft version published in December. 2 April 2013
Asia
There are important differences between the Russian and Eurasian procedures in obtaining a patent, especially for inventions in the field of life sciences, as Maria Nilova and Elena Tsvetkova explain. 1 April 2013
Americas
While no court has tested it, Brazilian legislation seems to prohibit pay-for-delay settlements in the pharmaceutical industry. Gabriel Di Blasi argues that it’s time for a test case. 1 April 2013
Asia
To read much of the reaction to recent pharmaceutical rulings in India, you might think that the country is waging a war against Western innovation. But while there is certainly cause for concern, that’s not the whole story, as LSIPR finds out. 1 April 2013